Economics of Industry

OHE’s Yan Feng, Mike Herdman, David Parkin and Nancy Devlin have a new paper in Quality of Life Research to exploring whether patients’ self-reported pain can be compared and aggregated in multi-country studies

Just published is a new report entitled: Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value. The publication is a report of the 2016 ICER Membership Policy Summit.

This is part one of two posts containing posters and presentations by members of the OHE team at ISPOR’s 21st Annual International Meeting held in Washington DC, 20-25th May 2016.

This study provides an analytical framework, drawing on production function theory, to identify and quantify the determinants of relative effectiveness and sources of variation in the relative effectiveness of treatments between populations and healthcare systems.

OHE’s Yan Feng and Jorge Mestre-Ferrandiz have co-authored a new publication on quantifying the spillovers between public and private sector biomedical and health research and development funding in the UK.

OHE’s Amanda Cole co-authors a new publication on the headroom approach, which can help assess the commercial value and viability of medical device development.

Just published by the World Dementia Council and OHE is an analysis which sets out the dementia R&D landscape. This analysis was undertaken by OHE for Imperial College and the UK Department of Health.

Marsden, G. and Mestre-Ferrandiz, J.

Research Paper
November 2015

This OHE Research Paper provides an overview of the current dementia R&D landscape. The research was undertaken by OHE for Imperial College and the UK Department of Health.

Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. We explore the feasibility of implementing MIP in the UK.

Mestre-Ferrandiz, J., Towse, A., Dellamano, R. and Pistollato, M.

Seminar Briefing
October 2015

Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. As value is likely to differ across major indications, if prices paid for on-patent medicines are to reflect their value, then multi-indication medicines should have different prices across major indication, reflecting different values.

Pages

Subscribe to RSS - Economics of Industry